Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Alumis Inc.

35 indications, side-by-side phase, drug & LoA

$24.15

+3.25 (+15.55%)

B 60Pipeline Score Fair Value Pharma · Commercial
Market Cap
2.81 B
EPS
-1.92
P/E Ratio
-
Value Trade
23.14 M
SEC Financials
Q1 2026

  • Dilution Risk

    15%

  • Revenue

    1.74 M

  • R&D Expenses

    81.54 M

  • Operating CF

    -87.08 M

  • Total Assets

    671.59 M

  • Total Liabilities

    104.57 M

  • Equity

    567.02 M

  • D/E Ratio

    12,345

-2.35 %
Week
-13.07 %
1 Month
-22.87 %
3 Month
221.46 %
6 Month
63.11 %
5 Year
63.11 %
All Time
Cash Data
Stable

  • Cash Position

    569.55 M

  • Monthly Burn

    29.03 M

  • Runway

    18.7 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 14, 2026
Overview
Volume
2.25 M
52 Week Range
2.76 - 30.60
% held by Insiders
34.35 %
% held by Institutions
67.27 %
Enterprise Value
2.32 B
Total Shares
123.16 M
Short %
15.58 %
Float Shares
71.06 M
Company Description
HQ: 280 EAST GRAND AVENUE, SOUTH S...
Employees:227
https://www.alumis.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 2b data readout example
ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE)
Phase 2b
—
Small Molecules
Immunology
ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE)
Phase 2b
—
Small Molecules
Immunology
ESK-001 (next-generation oral TYK2 inhibitor) systemic lupus erythematosus (SLE)
Phase 2b
—
Small Molecules
Immunology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B60
Pipeline Score
$3.9B
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.4x
rNPV / MCap
Top 89%
Small Cap
(rank 101 of 905)
Percentile Rank
Alumis Inc. holds a solid B-grade pipeline (60/100), with $6.3B risk-adjusted pipeline value, led by envudeucitinib in Plaque Psoriasis (Phase 3), across $82B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
envudeucitinib
Small molecule		Plaque PsoriasisPhase 3NCT0573943558% $5.0B ACTIVE NOT_RECRUITING 3,619 AVERAGE C (52) Dec 30, 2026LOW_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
envudeucitinib
moderate-to-severe plaque psoriasis,systemic lupus erythematosus
Phase 2
2025-11-14
envudeucitinib
moderate-to-severe plaque psoriasis,systemic lupus erythematosus
Phase 2
2025-11-14
envudeucitinib
moderate-to-severe plaque psoriasis,systemic lupus erythematosus
Phase 2
2025-11-14
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ALMS
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Alumis Inc. (ALMS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ALMS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ALMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
2026-09-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Alumis Inc. (ALMS) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ALMS ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Psoriasis #5 of 15 PHASE 3 Open-Label Envudeucitinib + Blinded Envudeucitinib
JNJ BMY ABBV
$26.66B 0.94 CONTENDER
Systemic Lupus Erythematosus #11 of 32 PHASE 2 Envudeucitinib
BIIB BMY VTRS
$2.78B 0.85 FOLLOWER